Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

The World Health Organization on Tuesday launched a new platform providing cost-free cancer medicines for thousands of ...

French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

Bavarian Nordic is now catching up to Valneva, whose Ixchiq vaccine became the world’s first licensed chikungunya vaccine ...

These vaccine candidates emphasize safety but may not be ideal for markets in developing countries due to their high cost and/or the requirement for multiple doses. A live, rationally attenuated ...

Credit: Soumyabrata Roy via Getty Images. Bavarian Nordic’s chikungunya vaccine Vimkunya is one step closer to being available in Europe after having secured an European Medicines Agency (EMA) ...

Saint Herblain (France), January 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32.8 million contract with the ...

Ixchiq Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 The Business Research Company’s Ixchiq Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 20 ...

What Are The Emerging Trends In The ixchiq Market? Key trends emerging in the Ixchiq market include the development of a chikungunya vaccine. A notable instance is Valneva SE, a France-based ...